Bemnifosbuvir (BEM)

DRUG4 trials

Sponsors

Atea Pharmaceuticals, Inc.

Conditions

COVID-19Healthy VolunteerHealthy Volunteer StudyHepatic ImpairmentSevere Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)

Phase 1

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

CompletedNCT05724693

Atea Pharmaceuticals, Inc.Healthy Volunteer, Hepatic Impairment

Start: 2023-01-30End: 2024-04-23Updated: 2024-07-31

Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects

CompletedNCT05905484

Atea Pharmaceuticals, Inc.Healthy Volunteer Study

Start: 2023-04-25End: 2023-05-31Updated: 2023-06-15

The Study of Bemnifosbuvir in Healthy Japanese Subjects

CompletedNCT05905497

Atea Pharmaceuticals, Inc.Healthy Volunteer Study

Start: 2023-04-26End: 2023-05-19Updated: 2023-06-15

Phase 3

SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

CompletedNCT05629962

Atea Pharmaceuticals, Inc.COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)

Start: 2022-11-25End: 2024-05-30Updated: 2025-06-13

Related Papers

Oral Bemnifosbuvir (AT-527) Vs Placebo in Patients With mild-to-moderate COVID-19 in an Outpatient Setting (MORNINGSKY)

Future Virology2023-09-0117 citations

Phase II Study of Bemnifosbuvir in High-Risk Participants in a Hospital Setting with Moderate COVID-19

Future Virology2023-06-0111 citations